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Castrate Resistant Prostate Cancer (CRPC) is a difﬁcult entity to treat in the spectrum of prostate cancer
disease. Recently, Follicle Stimulating Hormone (FSH) has been shown to play an important part in the
natural history of prostate cancer disease progression (Crawford et al., 2014). Here, we discuss a now
deceased 94 year-old patient who illustrates the importance of this.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Castrate Resistant Prostate Cancer (CRPC) is a difﬁcult entity to
treat in the spectrum of prostate cancer disease. Recently, Follicle
Stimulating Hormone (FSH) has been shown to play an important
part in the natural history of prostate cancer disease progression.1
Here, we discuss a now deceased 94 year-old patient who illus-
trates the importance of this.Case report
History
EM is a 94 year-old male who initially presented to our clinic in
2009. He has a history of macular degeneration, osteoarthritis,
abdominal aortic aneurysm and a radical retropubic prostatectomy
in 1996 after workup showed elevated prostate speciﬁc antigen
(PSA) and a positive biopsy showing Gleason 7 prostate cancer.
Pathology following surgery revealed Gleason 4 þ 5 ¼ 9. He
developed a rising PSA and had a biopsy proven Gleason 4 þ 4 ¼ 8
recurrence in his prostate bed in 1998. This leads to radiation and 6
cycles platinum based chemotherapy. He also had a bilateral
orchiectomy in 1999 given his recurrence in an effort to suppress
his testosterone levels. His PSA remained undetectable up until
2007, when it was found to be elevated to 10.0 ng/mL.du (S. Catarinicchia).
Inc. This is an open access article uHe was then seen in our multidisciplinary Urologic Oncology
clinic given his biochemical failure and castrate resistant prostate
cancer in 2009. He was initially placed on dutasteride and bica-
lutamide, however, his PSA continued to rise from 10 to 32.8
within the ﬁrst 6 months of follow up. Given this, he was started
on the LHRH antagonist degarelix in 9/2009. Throughout his
course, bone scans remained negative for metastasis. Despite
initiation of degarelix, his PSA slowly continued to rise, and in
2012, he was considered for additional, alternative therapies.
When he developed a positive bone scan, provenge therapy was
added in 1/2012 of which he received three infusions. He was then
continued on androgen deprivation therapy with degarelix until
1/2014, at which time it was discontinued. Abiraterone was then
started on 1/2015. Notably, his FSH started to rise again in this
time, and degarelix was again restarted in 4/2015, which resulted
in an FSH level that was <1 (see Table 1 as well as Fig. 1). Overall,
the patient’s PSA levels have come down with combination of
abiraterone and degarelix, suggesting the inﬂuence of both
testosterone and FSH on PSA levels (Fig. 2). He recently passed
away secondary to complications of pneumonia, and autopsy was
performed. His autopsy showed a focus of residual prostate
adenocarcinoma, G 5 þ 5 in a focus on lymph nodes subadjacent
to the bladder on the right. There was also no evidence of bony
metastasis, despite positive bone scan. The disease remained
localized to the pelvis, suggesting direct extension or local
metastasis of primary tumor. There were also small cell features
upon further analysis and immunostaining of the tissue. Inter-
estingly, his adrenals also showed cortical hyperplasia, possibly
due to his hormonal therapies.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Various laboratory investigations launched during treatment course
LH (mIU/mL) FSH (mIU/mL) PSA (ng/mL) Testosterone (ng/dL)
2010 <1.0 2 36/ 29/ 62 38/ 45/ 27
2011 NR NR 60/ 126 <20
2012 NR NR 161/ 270 <20
2013 <0.2 2 373/ 481 <20
2014 8/ 11 22/ 25 610/ 697 <20
2015 10/ <0.2 27/ 30/ <1 293/ 178 <20
Figure 1. The effect of various therapies on FSH in our patient.
Figure 2. The effect of various therapies on our patient’s PSA levels.
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The approach to evaluating and caring for the prostate cancer
patient has become multi-modal, with new data and strategies
entering the literature daily. One area of recent interest has been
the involvement of the GnRH, FSH, and LH pathway and its role in
prostate cancer. Multiple studies have shown that both benign and
malignant human prostate cells produce both FSH and its recep-
tor,2e6 with a propensity for increased FSH receptor gene expres-
sion inmalignant prostate cells.4 Speciﬁcally, FSHmay be important
in tumor invasion, as evidenced by FSH receptor expression on the
luminal endothelial surface found during intravasation.6 Both the
testes and prostate produce an important modulator of the FSH
pathway, Prostatic Inhibin Peptide (PIP). PIP decreases FSH pro-
duction and secretion from both the anterior pituitary and the
prostate. Its role has been demonstrated in mouse models injected
with castration-resistant CaP cells. Daily PIP treatment over
2 weeks signiﬁcantly decreased tumor growth and FSH levels (38%
and 60%, respectively), again demonstrating the importance of FSH
and its physiologic effect on prostate cancer tumor growth.7 This is
important when considering bilateral orchiectomy, such as our
patient had, as elimination of PIP from the hormonal pathway
would then lead to largely unregulated FSH levels and the subse-
quent physiologic effects of FSH on prostate cancer cells.
Notably, our patient had an increased testosterone level despite
bilateral orchiectomy when he established care with our clinic. This
may be explained by both adrenal sources of testosterone, as well as
production by castrate resistant prostate cancer cells themselves.
Several recent studies have shown that intratumoral production of
testosterone can occur, and is the therapeutic rationale behind
medications such as abiraterone and enzalutamide in advanced
castration resistant prostate cancer.8e10
The effects of a GnRH antagonist were clearly demonstrable in
our patient. His FSH level was largely undetectable, until ADT was
held for 1 year, at which time his FSH and LH rose, with a dramatic
increase in PSA during that time as well. Notably, his testosterone
levels remained less than 20 during that time, suggesting the
mitogenic effects of FSH on prostate cancer cells in the setting of
little to no testosterone detected in serum. Additionally, his FSH
levels came down to less than 1 when restarted on his GnRH
antagonist, along with his PSA.
The presence if Gleason 5 þ 5 ¼ 10 prostate cancer on autopsy
illustrates the importance of obtaining negative margins during
surgical resection, as well as a thorough lymph node dissection in
aggressive disease. The presence of Gleason 10 suggests the longterm effect of untreated castrate resistant cancer, as the histology
was more advanced than his initially pathology from his ﬁrst sur-
gery. This focus may also be responsible for increased testosterone
levels despite bilateral orchiectomoy. Overall, the autopsy in this
patient was an important addition in understanding his speciﬁc
disease, and particular response to various treatments. This could
be employed more frequently as we aim to understand disease
response to novel therapeutics.
In short, a patient centered, disease speciﬁc approach can be
useful when treating prostate cancer. Future research tailored to
understanding disease response to manipulation of the hormonal
milieu will be helpful in providing tailored care based on an in-
dividual’s disease and its speciﬁc response to hormones. Addi-
tionally, post mortem analysis can be useful in understanding
response to novel therapeutics. Despite increasing the complexity
of treatment paradigms, novel therapies such as LHRH antagonists
arewelcome additions to the urologic oncologist’s armamentarium.Conﬂict of interest
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